Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing the life expectancy WW. However, this has not translated into any reduction in the incidence or prevalence of chronic or critical illnesses! On the contrary the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected to
achieve sales in excess of trillion dollar mark by 2020 By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic have reached a critical mass warranting a close watch for those interested in keeping pace with the development of new medicines
The report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. The therapy class report highlights the future potential of this stream of medicine and the radical way diseases could be treated in the next few decades. This new stream of medicine is driven by landmark scientific discoveries and research (Nobel prize in 2012).
Table Of Contents
EXECUTIVE SUMMARY
• INTRODUCTION
• Tough Choice- Autologous vs. Allogenic " Therapies
• REGULATORY GUIDELINES
• Marketed Cell based/Stem Cell Products
• Progress and Challenges
• Progress in Specific Therapy Areas
• SELECT UPCOMING MILESTONES IN REGENERATIVE MEDICINE/STEM
CELL FOCUSED COMPANIES (2015-16)
• Appendix
List Of Tables
Table 1: Regenerative Medicine : MARKETED PRODUCTS IN KOREA
Table 2: MARKETED PRODUCTS WW
Table 3: COST OF TREATMENT OF APPROVED CELL THERAPIES
Table 4: NOTEWORTHY M&A (2013-14)
Table 5 : SELECT UPCOMING MILESTONES IN REGENERATIVE MEDICINE/STEM
CELL FOCUSED COMPANIES (2015-16)
Table 6:
List Of Figures
Figure 1:STEM CELLS- THE BACKBONE OF REGENERATIVE MEDICINE
Figure 2: DIFFERENT TYPES OF MSC USED IN THE CLINIC
Figure 3: DRUGS IN CLINICAL TRIAL - BY CELL TYPE
Figure 4: INDICATIONS BEING PURSUED IN REGENERATIVE MEDICINE/STEM
Figure 13: THERAPY PIPELINE: IMMUNOLOGY AD INFLAMMATION
Figure 12: THERAPY PIPELINE: DERMATOLOGY
Figure 3: Global Tissue Engineering Cell Therapy and Transplantyation Market, by Clinical Area, 2009-2018
Figure 5: JAPAN LEADS IN BRINGING THE REGULATORY CHANGES TO
ACCELERATE THE PACE OF DEVELOPMENT OF
THERAPIES IN REGENERATIVE MEDICINE
Appendix:
Figure 1 : Financing from March 2013 to March 2014
Figure 2 : Percent of comapanies that Consider the therapeutic Area as Highly opportunities for Regenerative Medicine
CELL THERAPY
Figure 4: Global Tissue Engineering & Cell Therapy Market, By Region , 2009-2018
Figure 5 : THERAPY PIPELINE: ONCOLOGY
Figure 6: THERAPY PIPELINE: ENDOCRINE AND GENETIC DISORDERS
Figure 7:THERAPY PIPELINE: GENITOURINARY DISORDERS
Figure 8 : THERAPY PIPELINE: GASTROENTEROLOGY
Figure 9 : THERAPY PIPELINE: CENTRAL NERVOUS SYSTEM
Figure 10: THERAPY PIPELINE: OPHTHALMOLOGY
Figure 11: THERAPY PIPELINE: HEMATOLOGY
